Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 11:31 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 539 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eruption Clear all
Completed Phase 1Phase 2 Interventional

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix

NCT00129428
View directory record Official record
Conditions
Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
Interventions
UVB Irradiation
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Nov 2, 2026, 11:31 AM EST
Recruiting Phase 4 Interventional

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

NCT07396168
View directory record Official record
Conditions
Lichen Plano-Pilaris
Interventions
Nemolizumab
Drug
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

NCT02250430
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 2 Interventional Results available

Dexamethasone Solution for the Treatment of Oral Lichen Planus

NCT02850601
View directory record Official record
Conditions
Lichen Planus
Interventions
Dexamethasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Nov 2, 2026, 11:31 AM EST
Completed Not applicable Interventional

A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants

NCT05094700
View directory record Official record
Conditions
Dermatitis, Atopic, Rosacea, Acne Vulgaris, Sensitive Skin
Interventions
Non-marketed Cosmetic Facial Cleanser
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Nov 2, 2026, 11:31 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers

The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol

NCT03563365
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Replenix Power of 3 Cream with resveratrol, Adapalene and Benzoyl peroxide gel, 0.1%/2.5%
Other · Drug
Lead sponsor
Yardley Dermatology Associates
Other
Eligibility
12 Years to 40 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Yardley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

NCT01831960
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Boise, Idaho • Carmel, Indiana • Clinton Township, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 2 Interventional

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

NCT01874860
View directory record Official record
Conditions
Colorectal Cancer, Head and Neck Cancer
Interventions
Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid)
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

NCT06063473
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
762 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

NCT01755247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Nov 2, 2026, 11:31 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne

NCT05919810
View directory record Official record
Conditions
Acne Vulgaris, Acneiform Eruptions, Skin Diseases, Sebaceous Gland Diseases
Interventions
Probiotic, Oral herbal powder supplement
Other · Dietary Supplement
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
12 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Nov 2, 2026, 11:31 AM EST
Withdrawn Phase 4 Interventional

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

NCT01299220
View directory record Official record
Conditions
Skin Rash
Interventions
Acitretin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 3 Interventional Results available

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

NCT00688064
View directory record Official record
Conditions
Severe Acne Vulgaris
Interventions
Adapalene BPO Gel associated with Doxycyline Hyclate, Vehicle Gel associated with Doxycycline Hyclate
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Oceanside, California • San Diego, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

NCT03003247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
364 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
20
States / cities
Encino, California • Lake Mary, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Nov 2, 2026, 11:31 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Sebum Collection and Skin Barrier Function Analysis

NCT03112876
View directory record Official record
Conditions
Smoking, Acne, Atopic Dermatitis, Aging
Interventions
Skin Surface Lipid Collection and Skin Barrier Function
Other
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 2 Interventional

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

NCT01194375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Low Strength IDP-107, High Strength IDP-107, Placebo
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
12 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
17
States / cities
Oceanside, California • Denver, Colorado • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Nov 2, 2026, 11:31 AM EST
Completed Early Phase 1 Interventional

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT03471364
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Danville, Illinois • Urbana, Illinois • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 2, 2026, 11:31 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Almond Supplementation on Mild to Moderate Acne

NCT05269641
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Food: whole almonds, Food: non-nut snack
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
15 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

NCT03497897
View directory record Official record
Conditions
Inflammatory Acne
Interventions
LYS006 20 mg, LYS006 2 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Fremont, California • Santa Monica, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

NCT02267746
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
14
States / cities
Encino, California • Fremont, California • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Nov 2, 2026, 11:31 AM EST
Completed Not applicable Interventional

Improving Disease Severity

NCT05391178
View directory record Official record
Conditions
Psoriasis, Alopecia Areata, Polymorphous Light Eruption
Interventions
Lumiton yarn sleeve, Lumiton yarn hat, Lumiton yarn shirt
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 2, 2026, 11:31 AM EST
Completed No phase listed Observational Results available

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT00709878
View directory record Official record
Conditions
Skin Rash
Interventions
Skin Biopsy of Skin Rash Secondary to EGFRI Use
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Nov 2, 2026, 11:31 AM EST
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Nov 2, 2026, 11:31 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Development and Validation of a Quality of Life Instrument for Actinic Keratosis

NCT01444989
View directory record Official record
Conditions
Actinic Keratosis
Interventions
AKRQ questionnaire, Skindex-16, DLQI, Skin Health Calculator
Other
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Nov 2, 2026, 11:31 AM EST